drugset / Trial / NCT06810492
The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment
NaSingle-groupOpen-labelTreatment
Summary
To explore the efficacy and safety of CDK4/6 inhibitors combined with endocrine neoadjuvant therapy for stage II-III HR-positive/HER2-negative breast cancer. This study adopts a single-arm, open-label design, and plans to include 40 patients with stage II-III HR+/HER2- breast cancer.
Timeline
- Start
- 2025-04-01
- Primary completion
- 2025-12-30
- Completion
- 2027-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 150 mg | Oral |
| Subject | Anastrozole | Other / unclassified | — | — |
| Subject | Dalpiciclib | Small molecule | 125 mg | Oral |
| Subject | Letrozole | Other / unclassified | — | — |
| Subject | Palbociclib | Small molecule | 125 mg | Oral |
| Subject | Ribociclib | Small molecule | 400 mg | Oral |
| Background | Esomeprazole | Small molecule | — | — |